Compare GORO & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | CCCC |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | 110 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 207.4M |
| IPO Year | N/A | 2020 |
| Metric | GORO | CCCC |
|---|---|---|
| Price | $1.60 | $2.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.75 | ★ $7.25 |
| AVG Volume (30 Days) | ★ 11.7M | 1.5M |
| Earning Date | 11-04-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,430,000.00 | $30,108,000.00 |
| Revenue This Year | $8.76 | N/A |
| Revenue Next Year | $85.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.29 | $1.09 |
| 52 Week High | $1.87 | $3.84 |
| Indicator | GORO | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 65.74 | 42.37 |
| Support Level | $0.95 | $2.07 |
| Resistance Level | $1.87 | $2.23 |
| Average True Range (ATR) | 0.21 | 0.13 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 71.37 | 5.32 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.